Clinical characterization of arrhythmia-induced tachymyopathy (AIC)

• Conditions: I42.9; I50.1; Cardiomyopathy, unspecified; Left ventricular failure

• Registration Number: DRKS00017515
• Lead Sponsor: niversitätsklinikum Regensburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-09-30
• Study Completion: 2021-04-23
• Results First Posted: 2021-10-14
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Suptraventricular tachycardia (100/min), unexplained left ventricular systolic dysfunction (LVEF <50%), rhythm control strategy, age >18y, informed consent.

Exclusion Criteria

History of previous significant non AIC-LVSD (EF<50%), myocardial infarction within the last 3 months. Long persistent or permanent AF.

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The dual primary end point ‘prevalence of arrhythmia-indced cardiomyopathy and time to recovery of systolic heart function” is determined after the outpatient visit at six months. The prevalence of AIC is calculated by the quotient from the number of patients in arm 1 and the total number of patients. For the classification in the specific study arm, LVEF is used, which is measured by echocardiography.